BIOBANK  login

Functional Precision Medicine Successfully Guides Therapeutic Regimen of ‘Cancer of Unknown Primary’ Later Classified as Triple-Negative Breast Cancer: A Case Report

Ruhe L, Heibl S, Czompo M, Haybaeck J, Loskutov J, Regenbrecht MJ, Thaler J, Wedeken L, Regenbrecht CRA. Functional precision medicine successfully guides therapeutic regimen of ‘cancer of unknown primary’ later classified as triple-negative breast cancer: a case report. Case Rep Oncol. Case Rep Oncol (2024) 17 (1): 490–496. doi: 10.1159/000538137

A combined computational and functional approach identifies IGF2BP2 as a driver of chemoresistance in a wide array of pre-clinical models of colorectal cancer

Kendzia S, Franke S, Kröhler T, Golob-Schwarzl N, Schweiger C, Toeglhofer AM, Skofler C, Uranitsch S,_x000D_El-Heliebi A, Fuchs J, Punschart A, Stiegler P, Keil M, Hoffmann J, Henderson D, Lehrach H, Yaspo M, Reinhard_x000D_C, Schäfer R, Keilholz U, Regenbrecht C, Schicho R, Fickert P, Lax SF, Erdmann F, Schulz MH, Kiemer_x000D_AK, Haybaeck J, Kessler SM: […]

RNA sequencing of long-term label-retaining colon cancer stem cells identifies novel regulators of quiescence

Regan JL, Schumacher D, Staudte S, Steffen A, Lesche R, Toedling J, Jourdan T, Haybaeck J, Mumberg D,_x000D_Henderson D, Győrffy B, Regenbrecht CRA, Keilholz U, Schäfer R, Lange M. RNA sequencing of long-term_x000D_label-retaining colon cancer stem cells identifies novel regulators of quiescence. iScience. 2021 May_x000D_24;24(6):102618. doi: 10.1016/j.isci.2021.102618. PMID: 34142064; PMCID: PMC8185225.

Peritoneal metastasis of colorectal cancer (pmCRC): identification of predictive molecular signatures by a novel preclinical platform of matching pmCRC PDX/PD3D models

Dahlmann M, Gambara G, Brzezicha B, Popp O, Pachmayr E, Wedeken L, Pflaume A, Mokritzkij M, Gül-_x000D_Klein S, Brandl A, Schweiger-Eisbacher C, Mertins P, Hoffmann J, Keilholz U, Walther W, Regenbrecht C,_x000D_Rau B, Stein U. Peritoneal metastasis of colorectal cancer (pmCRC): identification of predictive molecular_x000D_signatures by a novel preclinical platform of matching pmCRC PDX/PD3D models. […]

Heterogeneous pathway activation and drug response modelled in colorectal-tumorderived 3D cultures

Schumacher D, Andrieux G, Boehnke K, Keil M, Silvestri A, Silvestrov M, Keilholz U, Haybaeck J, Erdmann G,_x000D_Sachse C, Templin M, Hoffmann J, Boerries M, Schäfer R, Regenbrecht CRA: Heterogeneous pathway activation_x000D_and drug response modelled in colorectal-tumor-derived 3D cultures. PLoS Genet. 2019 Mar_x000D_29;15(3):e1008076. doi: 10.1371/journal.pgen.1008076. Erratum in: PLoS Genet. 2019 May 29;15(5):e1008183._x000D_PMID: 30925167; PMCID: PMC6457557.

Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors

Moritz Schütte, Thomas Risch, Nilofar Abdavi-Azar, Karsten Boehnke, Dirk Schumacher, Marlen Keil, Reha_x000D_Yildiriman, Christine Jandrasits, Tatiana Borodina, Vyacheslav Amstislavskiy, Catherine L. Worth, Caroline_x000D_Schweiger, Sandra Liebs, Martin Lange, Hans- Jörg Warnatz, Lee M. Butcher, James E. Barrett, Marc_x000D_Sultan, Christoph Wierling, Nicole Golob-Schwarzl, Sigurd Lax, Stefan Uranitsch, Michael Becker, Yvonne_x000D_Welte, Joseph Lewis Regan, Maxine Silvestrov, Inge Kehler, […]